GHRP-6
Educational information only — not medical advice. Many listed compounds are not FDA-approved for human use. Consult a licensed clinician before starting, changing, or stopping any protocol.
Overview
GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide — a chain of six amino acids — classified as a growth hormone secretagogue. It is studied for its ability to prompt the pituitary gland to release growth hormone in short, natural-looking pulses.
GHRP-6 is best known for one distinctive property: a strong increase in appetite. This makes it a frequent subject of research in contexts where appetite stimulation is of interest, and it is a trait that sets it apart from several other peptides in the same family.
Most of the evidence comes from animal models and early human pharmacology studies. GHRP-6 is not approved by any major regulator for therapeutic use and is sold for research purposes only.
How it works
GHRP-6 acts as an agonist at the growth hormone secretagogue receptor (GHS-R1a) — the same receptor targeted by ghrelin, the body’s principal hunger hormone. By mimicking ghrelin at this receptor, it both stimulates growth hormone release from the pituitary and engages the brain’s appetite centers, which is thought to explain its orexigenic (hunger-promoting) effect.
Its growth-hormone effect appears to depend partly on the body’s own signaling: human studies suggest that endogenous growth hormone releasing hormone (GHRH) is needed for a maximal GH response to GHRP-6. The precise mechanism and long-term effects in humans are not fully established.
Reported benefits
- Stimulation of pulsatile growth hormone release (studied in animals and early human pharmacology)
- Marked appetite stimulation (a consistently reported effect)
- Interest as a research tool for studying the ghrelin/GH-secretagogue system
These are reported and studied effects, not guaranteed outcomes.
Considerations & side effects
Because rigorous long-term human trials are lacking, the safety profile of GHRP-6 is not well characterized. Commonly reported effects include a pronounced increase in hunger, injection-site irritation, water retention, and transient flushing or lightheadedness. Some animal data suggest its effects on weight and fat mass may vary with insulin and glucose status.
Product purity varies widely in the research-chemical market. GHRP-6 is not a substitute for evaluation and treatment by a qualified clinician.
Frequently asked
What is GHRP-6?
A synthetic six-amino-acid peptide (a growth hormone secretagogue) that stimulates the pituitary to release growth hormone and is well known for markedly increasing appetite.
Is GHRP-6 FDA-approved?
No. GHRP-6 is not approved by the FDA or any major regulator for human therapeutic use, and is sold for research purposes only.
Why is GHRP-6 associated with hunger?
It activates the same receptor as ghrelin, the body's main hunger hormone, so a pronounced increase in appetite is one of its most commonly reported effects.
How is GHRP-6 typically administered?
Most commonly by subcutaneous or intramuscular injection after reconstitution with bacteriostatic water.
How does it differ from other GHRPs?
Among the growth hormone releasing peptides, GHRP-6 is the one most associated with strong appetite stimulation; related peptides such as GHRP-2 or ipamorelin are often described as having a milder effect on hunger.
References
- Lawrence CB, et al. Acute central ghrelin and GH secretagogues induce feeding and activate brain appetite centers. ↗
- Pandya N, et al. GH-releasing peptide-6 requires endogenous hypothalamic GH-releasing hormone for maximal GH stimulation. ↗
- Granado M, et al. The positive effects of GHRP-6 on weight gain and fat mass accrual depend on the insulin/glucose status. ↗
Related compounds
Modified GRF (1-29). Growth hormone releasing hormone analog. Often combined with Ipamorelin for synergistic GH release.
CJC-1295 with Drug Affinity Complex. Extended half-life version providing sustained GH elevation. Once or twice weekly dosing.
Triple GH secretagogue blend combining CJC-1295 (no DAC / Mod GRF 1-29) with two ghrelin mimetics, ipamorelin and GHRP-2, for amplified synergistic GH release. Sold as a single 9mg lyophilized vial.